What is the appropriate dosing for norepinephrine (Levophed) and what considerations should be taken into account when selecting a second vasopressor?

Norepinephrine Dosing and Second Vasopressor Selection

Start norepinephrine at 8-12 mcg/min (0.05-0.1 mcg/kg/min), titrate to MAP ≥65 mmHg, and add vasopressin 0.03 units/min as your second vasopressor when norepinephrine requirements reach moderate doses, rather than continuing to escalate norepinephrine alone. 1, 2

Norepinephrine: First-Line Vasopressor

Norepinephrine is unequivocally the first-choice vasopressor for septic shock 2. The Surviving Sepsis Campaign guidelines provide strong recommendations (Grade 1B) based on its superior safety profile compared to alternatives like dopamine, which increases arrhythmic events without survival benefit 2.

Initial Dosing Protocol

Preparation and Administration:

• Dilute 4 mg norepinephrine in 1,000 mL of 5% dextrose solution (yielding 4 mcg/mL concentration) 1
• Never use saline alone as the diluent—dextrose protects against oxidation and potency loss 1
• Administer through a large central vein via secure IV catheter 1

Starting Dose:

• Begin at 2-3 mL/min of the diluted solution (8-12 mcg/min of norepinephrine base) 1
• Titrate rapidly to achieve MAP ≥65 mmHg 2
• Average maintenance dose: 2-4 mcg/min (0.5-1 mL/min) 1

Critical Caveat: Ensure adequate fluid resuscitation (minimum 30 mL/kg crystalloids) before or concurrent with vasopressor initiation 2, 1. Occult hypovolemia is the most common reason for apparent "refractory" shock requiring high vasopressor doses 1.

Dose Escalation Considerations

While norepinephrine can be titrated to very high doses (up to 68 mg/day documented in FDA labeling 1), escalating beyond moderate doses carries significant risks without clear benefit. High catecholamine exposure is associated with:

• Increased arrhythmias 3, 2
• Myocardial ischemia 3
• Excessive vasoconstriction compromising tissue perfusion 4
• Immune dysfunction 3

Second Vasopressor Selection

When norepinephrine alone is insufficient, add vasopressin 0.03 units/min rather than continuing to escalate norepinephrine. 2

Vasopressin as Second-Line Agent

The Surviving Sepsis Campaign guidelines recommend adding vasopressin (up to 0.03 units/min) to norepinephrine with two specific intents 2:

1. Raising MAP to target when norepinephrine alone is inadequate
2. Decreasing norepinephrine dosage to reduce catecholamine exposure

Key Dosing Points:

• Fixed dose: 0.03 units/min (not titrated) 2
• Do not use vasopressin as monotherapy for initial vasopressor support 2
• Doses >0.03-0.04 units/min should be reserved for salvage therapy only 2

Evidence Nuance: While the VASST trial showed no overall survival benefit from adding vasopressin, post-hoc analysis suggested potential benefit in patients with less severe shock (norepinephrine <15 mcg/min) 3. The VANISH trial confirmed no mortality difference but demonstrated synergistic effects with hydrocortisone 3. Despite lack of definitive survival benefit, vasopressin provides complementary non-adrenergic vasoconstriction and may improve renal perfusion 5, 6.

Alternative Second-Line Options

Epinephrine is the alternative second-line agent if vasopressin is unavailable or contraindicated 2:

• Can be added to or substituted for norepinephrine (Grade 2B) 2
• Achieves similar shock reversal as norepinephrine 3
• Optimal timing: Consider adding when norepinephrine-equivalent dose reaches 37-133 mcg/min for best hemodynamic response 7
• Higher risk of arrhythmias and metabolic derangements compared to vasopressin 3

Agents to Avoid:

• Dopamine: Reserve only for bradycardic patients with low arrhythmia risk 2. Associated with increased arrhythmic events without survival benefit 3, 2
• Phenylephrine: Use only in specific circumstances: norepinephrine-induced arrhythmias, documented high cardiac output with persistent hypotension, or salvage therapy 2
• Low-dose dopamine for renal protection: Strongly contraindicated (Grade 1A) 2

Practical Algorithm for Vasopressor Management

1. Ensure adequate volume resuscitation (≥30 mL/kg crystalloids) 2
2. Start norepinephrine at 8-12 mcg/min, titrate to MAP ≥65 mmHg 1, 2
3. If MAP target not achieved at moderate norepinephrine doses:
   • Add vasopressin 0.03 units/min 2
   • Alternative: Add epinephrine if vasopressin unavailable 2
4. If still refractory:
   • Reassess for occult hypovolemia (check CVP) 1
   • Consider inotropic support (dobutamine up to 20 mcg/kg/min) if evidence of persistent hypoperfusion despite adequate MAP 2
   • Evaluate for corticosteroid therapy 2

Monitoring Requirements

• Place arterial catheter as soon as practical for continuous blood pressure monitoring 2
• Monitor for extravasation—norepinephrine causes tissue necrosis if infiltrated 1
• Assess tissue perfusion markers (lactate clearance, urine output, mental status) beyond just MAP 4
• Gradually taper vasopressors when hemodynamic stability achieved; avoid abrupt withdrawal 1

Duration: Continue infusion until adequate blood pressure and tissue perfusion maintained without therapy; may require up to 6 days in severe cases 1.